SCHEMBL3853534

SCHEMBL3853534

CCOC(=O)c1c(O)c(C(C)C)nn(Cc2cc(Cl)ccc2Cl)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
HSD17B10 Q99714 1/20 0.39
P2RX3 P56373 1/20 0.38
PTGER1 P34995 2/20 0.37
CCR2 P41597 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3847540 0.92 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAHPGDMEN1
SCHEMBL3855997 0.88 ALDH1A1 (0.45) ALDH1A1PTGDR2KDM4ELMNAHPGD
SCHEMBL3850428 0.88 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAHPGDMEN1
SCHEMBL3856749 0.85 SMN1; SMN2 (0.43) ALDH1A1PTGDR2KDM4ELMNAHPGD
SCHEMBL3849126 0.84 ALDH1A1 (0.41) ALDH1A1KDM4ELMNAHPGDMEN1
SCHEMBL3849080 0.82 PDE4B (0.42) ALDH1A1KDM4ELMNAHPGDMEN1
SCHEMBL3847603 0.82 DPP4 (0.40) ALDH1A1PTGDR2KDM4ELMNAHPGD
SCHEMBL3853119 0.81 MAPK1 (0.55) ALDH1A1KDM4ELMNAHPGDMEN1
SCHEMBL3847214 0.80 EGLN3 (0.50) PTGDR2
SCHEMBL3851808 0.80 ALDH1A1 (0.42) ALDH1A1PTGDR2KDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN ALDH1A1 564/4885PTGDR2 590/4885KDM4E 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.